GLP-1 Agonists Tied to Lower Mortality in Severe Psychiatric Disorders
A large observational study found that adults with serious mental illness who started GLP-1 receptor agonists had a 24% lower risk of death over four years compared with those starting SGLT2 inhibitors. The benefit was mainly due to fewer cardiovascular events, including heart attacks and strokes. The findings suggest these drugs might help reduce the well-known lifespan gap for people with serious psychiatric conditions.
The retrospective analysis matched nearly 200,000 pairs of adults with serious mental illness, comparing GLP-1 users against SGLT2 inhibitor users. The mortality advantage was most pronounced during the first year, with a 49% relative risk reduction. Cardiovascular benefits drove the overall finding, with significant reductions in heart attacks, strokes, and heart failure.
People with serious psychiatric conditions typically live 10 to 25 years shorter than the general population, largely due to cardiovascular disease. The authors proposed that anti-inflammatory and anti-atherogenic effects of GLP-1 drugs, plus possible behavioral influences, may explain the benefit. They noted no FDA-approved psychiatric treatment has demonstrated mortality reduction of this magnitude.
This research could reshape how clinicians approach cardiometabolic risk in psychiatric populations, where premature death from heart disease has long been an accepted tragedy.